会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明申请
    • SYSTEM FOR REDUCTION OF AIR LEAKS WITH USE OF CPAP MASKS
    • 使用CPAP掩模减少空气泄漏的系统
    • US20140000615A1
    • 2014-01-02
    • US13784907
    • 2013-03-05
    • Alan Wanderer
    • Alan Wanderer
    • A61M16/06A61M16/00
    • A system of the invention is a housing-liner apparatus complex and/or eye shield comprising an air leak preventing system is provided for use with continuous positive airway pressure devices, e.g. CPAP mask. The system includes a housing-liner and/or an eye shield reversibly or irreversibly attached to a mask, and adjustable straps extending from the housing-liner and/or eye shield to attach onto a mask to create an improved seal between the mask and the user. Beneficially, the system muffles noise associated with air leakage, and reduces other side effects with CPAP masks, e.g. slippage of the lower part of the mask into the user's mouth and/or puffing out of cheeks during sleep. Furthermore, the system may include a chin support to reduce mouth opening of the user during sleep. Overall, the system creates greater user comfort by maintaining the interface between the mask and user's face during sleep.
    • 本发明的系统是一种外壳衬垫设备复合体和/或护眼罩,其包括防漏气系统,用于连续正气道压力装置,例如, CPAP掩码 该系统包括可逆地或不可逆地附接到面罩的壳体衬里和/或眼罩,以及从壳体衬垫和/或眼罩延伸的可调节带以附接到面罩上以在面罩和面罩之间形成改进的密封 用户。 有利地,该系统消除与空气泄漏相关的噪声,并且减少CPAP掩模的其他副作用,例如, 在睡眠期间将面罩的下部滑动到使用者的口中和/或从面颊吹出。 此外,系统可以包括下巴支持以减少睡眠期间用户的开口。 总体而言,该系统通过在睡眠期间保持面具和使用者的脸部之间的界面来创造更大的使用者舒适度。
    • 6. 发明申请
    • Rationale for IL-1 Beta targeted therapy in sickle cell disease for ischemia-reperfusion induced complications
    • IL-1β靶向治疗镰状细胞疾病缺血再灌注诱导并发症的理由
    • US20100233168A1
    • 2010-09-16
    • US12660981
    • 2010-03-09
    • Alan Wanderer
    • Alan Wanderer
    • A61K39/395A61P9/10A61P7/00
    • C07K16/245A61K2039/505
    • Sickle cell patients atypically experience exaggerated inflammatory responses to pathogens that normally cause mild respiratory infections in non-sickle cell humans. There appears to be heightened inflammatory responses to pathogens in combination with hypoxia in sickle cell disease. The novelty of this invention provides a new paradigm to explain the exaggerated inflammatory response of sickle cell disease to pathogens especially when accompanied by hypoxic stress. In particular, sickle cell chest injury and other complications associated with ischemia-reperfusion injury caused by vaso-occlusion can involve co-stimulation of the NALP-3 inflammasome by pathogen associated molecular patterns (PAMPs) and hypoxic-induced danger associated molecular patterns (DAMPs), leading to exaggerated pro-inflammatory responses marked by increased IL-1β secretion and subsequent induction of neutrophilic inflammation. This invention thereby provides the immunologic, biologic and biochemical rationale for IL-1β targeted therapies in sickle cell disease to block the pathological effects of IL-1β that leads to exaggerated inflammatory expressions, including neutrophilic inflammation.
    • 镰状细胞病人不典型地经历对非镰状细胞人通常引起轻度呼吸道感染的病原体的夸张的炎症反应。 在镰状细胞病中与病原体相结合的缺氧似乎有较高的炎症反应。 本发明的新颖性提供了一种新的范例来解释镰状细胞病对病原体的夸张的炎症反应,特别是伴随着缺氧应激时。 特别是镰状细胞胸部损伤和与血管闭塞引起的局部缺血 - 再灌注损伤有关的其他并发症可能涉及通过病原体相关分子模式(PAMP)和缺氧诱导的危险相关分子模式(DAMPs)共同刺激NALP-3炎性体 ),导致增加的IL-1和bgr标记的夸张的促炎反应; 分泌和随后诱导嗜中性粒细胞炎症。 因此本发明提供IL-1和bgr的免疫学,生物学和生物化学原理。 镰状细胞疾病的靶向治疗可阻断IL-1和bgr的病理作用; 导致夸张的炎症表达,包括嗜中性粒细胞炎症。